Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Campone

Showing results (1-10 of 302) with videos related to

Pageof 31
Sort By:
Transplantation|November 19, 2016
Daunting but Worthy Goal: Reducing the De Novo Cancer Incidence After TransplantationJacques Dantal, Mario Campone
Bulletin Du Cancer|April 10, 2002
[Weekly administration of paclitaxel in the treatment of metastatic breast cancer: from rational to practice]Mario Campone, Pierre Fumoleau
Bulletin Du Cancer|May 19, 2005
[Cardiac dysfunction induced by trastuzumab]Mario Campone, Emmanuelle Bourbouloux, Pierre Fumoleau
International Journal of Environmental Research and Public Health|June 24, 2022
The Challenges of Implementing Comprehensive Clinical Data Warehouses in HospitalsFrançois Bocquet, Mario Campone, Marc Cuggia
Expert Opinion on Pharmacotherapy|November 18, 2011
Eribulin mesylate for the treatment of late-stage breast cancerCarole Gourmelon, Jean Sébastien Frenel, Mario Campone
Bulletin Du Cancer|September 6, 2003
[Role of the combination of trastuzumab and taxanes in the therapeutic management of cancer of the breast: from preclinical data to clinical application]Mario Campone, Jean-Louis Merlin, Pierre Fumoleau
Expert Review of Anticancer Therapy|February 10, 2012
What is the best choice of partner chemotherapy with trastuzumab for metastatic breast cancer?Carole Gourmelon, Jean Sébastien Frenel, Mario Campone
Critical Reviews in Oncology/Hematology|August 6, 2010
Resistance to HER2 inhibitors: is addition better than substitution? Rationale for the hypothetical concept of drug sedimentationMario Campone, Philippe Juin, Fabrice André, et al.
International Journal of Environmental Research and Public Health|May 14, 2022
Supporting the Return to Work of Breast Cancer Survivors: From a Theoretical to a Clinical PerspectiveBertrand Porro, Mario Campone, Philippe Moreau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2008
Vinflunine: a new microtubule inhibitor agentJaafar Bennouna, Jean-Pierre Delord, Mario Campone, et al.
Pageof 31

Showing results (1-10 of 302) with videos related to

Sort By:
Pageof 31
Transplantation|November 19, 2016
Daunting but Worthy Goal: Reducing the De Novo Cancer Incidence After TransplantationJacques Dantal, Mario Campone
Bulletin Du Cancer|April 10, 2002
[Weekly administration of paclitaxel in the treatment of metastatic breast cancer: from rational to practice]Mario Campone, Pierre Fumoleau
Bulletin Du Cancer|May 19, 2005
[Cardiac dysfunction induced by trastuzumab]Mario Campone, Emmanuelle Bourbouloux, Pierre Fumoleau
International Journal of Environmental Research and Public Health|June 24, 2022
The Challenges of Implementing Comprehensive Clinical Data Warehouses in HospitalsFrançois Bocquet, Mario Campone, Marc Cuggia
Expert Opinion on Pharmacotherapy|November 18, 2011
Eribulin mesylate for the treatment of late-stage breast cancerCarole Gourmelon, Jean Sébastien Frenel, Mario Campone
Bulletin Du Cancer|September 6, 2003
[Role of the combination of trastuzumab and taxanes in the therapeutic management of cancer of the breast: from preclinical data to clinical application]Mario Campone, Jean-Louis Merlin, Pierre Fumoleau
Expert Review of Anticancer Therapy|February 10, 2012
What is the best choice of partner chemotherapy with trastuzumab for metastatic breast cancer?Carole Gourmelon, Jean Sébastien Frenel, Mario Campone
Critical Reviews in Oncology/Hematology|August 6, 2010
Resistance to HER2 inhibitors: is addition better than substitution? Rationale for the hypothetical concept of drug sedimentationMario Campone, Philippe Juin, Fabrice André, et al.
International Journal of Environmental Research and Public Health|May 14, 2022
Supporting the Return to Work of Breast Cancer Survivors: From a Theoretical to a Clinical PerspectiveBertrand Porro, Mario Campone, Philippe Moreau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2008
Vinflunine: a new microtubule inhibitor agentJaafar Bennouna, Jean-Pierre Delord, Mario Campone, et al.
Pageof 31